Latest Safety News

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Magnetic Resources NL’s Feasibility Study confirms a robust standalone development for its Lady Julie Gold Project in Western Australia, projecting over 1 million ounces of gold production across nine years with strong financial returns.

Nico Resources Limited reported steady progress on its Wingellina nickel-cobalt project despite challenging market conditions, completing a $1.1 million share placement and advancing metallurgical and drilling programs.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.

PPK Group’s majority-owned PowerPlus Energy launches two Clean Energy Council-approved batteries eligible for the Australian Government’s new Cheaper Home Batteries Program rebates, positioning itself to capture a significant share of the emerging residential energy storage market.

Aeris Resources reported a robust June 2025 quarter with increased copper and gold production, improved cost efficiencies, and successful refinancing, while advancing exploration at key projects.

Aurelia Metals has successfully met its FY25 production and cost guidance, while advancing key mining projects and maintaining a robust cash position of $110 million.

Aurelia Metals has successfully met its FY25 production and cost guidance, driven by a strong ramp-up at Federation Mine and the start of development at Great Cobar. The company’s solid quarterly performance underpins its growth ambitions for FY26.

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.

Regis Resources closed FY25 with gold production near the top of guidance and a robust cash and bullion position of $517 million. The company’s FY26 outlook maintains steady production while ramping up growth investments amid ongoing legal and exploration developments.